NASDAQ:AVGRAvinger Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avinger Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.40 +0.08 (+24.84 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$0.32Now: $0.40▼$0.4250-Day Range$0.28MA: $0.36▼$0.5152-Week Range$0.24Now: $0.40▼$5.70Volume8.93 million shsAverage Volume3.39 million shsMarket Capitalization$12.60 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAvinger has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.40, Avinger has a potential upside of 250.9% from its current price of $0.40.Amount of Analyst CoverageAvinger has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAvinger has received 362 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvinger has received 320 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvinger has received 53.08% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avinger and other stocks. Vote “Outperform” if you believe AVGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVGR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvinger does not currently pay a dividend.Dividend GrowthAvinger does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avinger insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.51% of the stock of Avinger is held by insiders.Percentage Held by InstitutionsOnly 7.34% of the stock of Avinger is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avinger are expected to grow in the coming year, from ($0.98) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avinger is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avinger is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvinger has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR Previous Symbol CUSIPN/A CIK1506928 Webwww.avinger.com Phone650-241-7900Debt Debt-to-Equity Ratio0.89 Current Ratio1.11 Quick Ratio0.85Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.13 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book2.87Profitability EPS (Most Recent Fiscal Year)($3.18) Net Income$-19,450,000.00 Net Margins-211.96% Return on Equity-270.15% Return on Assets-78.28%Miscellaneous EmployeesN/A Outstanding Shares31,340,000Market Cap$12.60 million Next Earnings Date7/29/2020 (Estimated) OptionableNot Optionable NASDAQ:AVGR Rates by TradingView Receive AVGR News and Ratings via Email Sign-up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Avinger (NASDAQ:AVGR) Frequently Asked Questions How has Avinger's stock been impacted by COVID-19 (Coronavirus)? Avinger's stock was trading at $0.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVGR shares have decreased by 7.2% and is now trading at $0.3990. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Avinger? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avinger. When is Avinger's next earnings date? Avinger is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Avinger. How were Avinger's earnings last quarter? Avinger Inc (NASDAQ:AVGR) issued its quarterly earnings results on Wednesday, May, 13th. The medical device company reported ($0.47) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.06. The medical device company had revenue of $2.26 million for the quarter. Avinger had a negative return on equity of 270.15% and a negative net margin of 211.96%. View Avinger's earnings history. When did Avinger's stock split? How did Avinger's stock split work? Avinger shares reverse split on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split. What guidance has Avinger issued on next quarter's earnings? Avinger updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.25-2.25 million, compared to the consensus revenue estimate of $2.56 million. What price target have analysts set for AVGR? 2 Wall Street analysts have issued 1 year target prices for Avinger's stock. Their forecasts range from $1.40 to $1.40. On average, they expect Avinger's stock price to reach $1.40 in the next year. This suggests a possible upside of 250.9% from the stock's current price. View analysts' price targets for Avinger. Has Avinger been receiving favorable news coverage? News articles about AVGR stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avinger earned a news impact score of -3.8 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAvinger. Who are some of Avinger's key competitors? Some companies that are related to Avinger include Neuronetics (STIM), Motus GI (MOTS), Sensus Healthcare (SRTS), Arch Therapeutics (ARTH), Neovasc (NVCN), Invo Bioscience (IVOB), Biostage (BSTG), DarioHealth (DRIO), Delcath Systems (DCTH), Atossa Genetics (ATOS), Interpace Diagnostics Group (IDXG), Titan Medical (TMDI), Endologix (ELGX), Dynatronics (DYNT) and Encision (ECIA). View all competitors. What other stocks do shareholders of Avinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include AcelRx Pharmaceuticals (ACRX), Actinium Pharmaceuticals (ATNM), Onconova Therapeutics (ONTX), Palatin Technologies (PTN), Biocept (BIOC), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Alibaba Group (BABA), Canopy Growth (CGC) and Genocea Biosciences (GNCA). Who are Avinger's key executives? Avinger's management team includes the following people: Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 57)Mr. Mark B. Weinswig, Chief Financial Officer (Age 46)Mr. Himanshu N. Patel, Chief Technology Officer (Age 59)Mr. Keith Schaefer, Chief Operating OfficerMr. Philip R. Preuss, VP of Marketing & Bus. Operations (Age 41) When did Avinger IPO? (AVGR) raised $60 million in an IPO on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." Who are Avinger's major shareholders? Avinger's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (7.52%) and Sabby Management LLC (1.93%). View institutional ownership trends for Avinger. Which major investors are buying Avinger stock? AVGR stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, and Perkins Capital Management Inc.. View insider buying and selling activity for Avinger. How do I buy shares of Avinger? Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.40. How big of a company is Avinger? Avinger has a market capitalization of $12.50 million and generates $9.13 million in revenue each year. The medical device company earns $-19,450,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. What is Avinger's official website? The official website for Avinger is www.avinger.com. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
